IDD-1

IDD-1 Uses, Dosage, Side Effects, Food Interaction and all others data.

Lipids promote the fusion of liposomes to cells. Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

IDD-1 specifically targets cancer cells by simulating a natural immune response. IDD-1 is produced by coupling dendritophages with tumor antigens obtained from the individual patient. The resulting vaccine is then reinjected into the subject.

Table Of contents

• IDD-1
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	IDD-1
Generic	IDD-1
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Investigated for use/treatment in prostate cancer.

How IDD-1 works

The lipid promotes fusion of liposomes to cells. Specifically, IDD-1 targets tumor cells by coupling dendritophages with tumor antigens obtained from the patient.

Toxicity

MoABs have been reported to have low toxicity, as they successfully target the tumor cells.

Elimination Route

3 doses x 3 cycles [each dose divided in 1 i.v.,4 s.c. and 1 i.d. injection]

Innovators Monograph

You find simplified version here IDD-1